• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.

    2/17/26 4:00:06 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Opus Genetics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    67577R102

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    67577R102


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,174,154.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,174,154.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,174,154.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    67577R102


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,174,154.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,174,154.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,174,154.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    67577R102


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,174,154.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,174,154.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,174,154.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Opus Genetics, Inc.
    (b)Address of issuer's principal executive offices:

    8 Davis Drive, Suite 220, Durham, NC, 27713
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Opus Genetics, Inc. (the "Issuer") are: Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. ("Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    67577R102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 68,964,208 outstanding shares of Common Stock as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 2,849,154 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds (i) 4,325,000 shares of Common Stock, (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 13,617,584 shares of Common Stock at an exercise price of $0.0001 per share, subject to the Beneficial Ownership Limitation (as defined below), and (iii) common warrants (the "Common Warrants," and together with the Pre-Funded Warrants, the "Warrants") to purchase 13,157,895 shares of Common Stock at an exercise price of $0.95 per share, subject to the Beneficial Ownership Limitation. The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Warrants for up to 2,849,154 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
    (b)Percent of class:

    Perceptive Advisors: 9.99% Mr. Edelman: 9.99% Master Fund: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 7,174,154 Mr. Edelman: 7,174,154 Master Fund: 7,174,154

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 7,174,154 Mr. Edelman: 7,174,154 Master Fund: 7,174,154

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:02/17/2026
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:02/17/2026
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:02/17/2026
    Get the next $IRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRD

    DatePrice TargetRatingAnalyst
    3/30/2026$15.00Overweight
    Cantor Fitzgerald
    3/16/2026$10.00Outperform
    Oppenheimer
    1/20/2026$7.00Buy
    BTIG Research
    12/10/2025$9.00Buy
    B. Riley Securities
    11/25/2025$7.00Overweight
    Piper Sandler
    10/29/2025$8.00Outperform
    Wedbush
    10/16/2025$9.00Buy
    Chardan Capital Markets
    4/11/2025$6.00Buy
    Craig Hallum
    More analyst ratings

    $IRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schachle Joseph K

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:12:35 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Zaremba Rabourn Amy

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:11:39 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Magrath George

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:10:31 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

    RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recogniz

    3/24/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics to Present at Upcoming Investor Conferences in March 2026

    RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences. Leerink Global Healthcare Conference Date: Tuesday, March 10, 2026Time: 3:00 p.m. ETLocation: Miami, FL Citizens Life Sciences Conference Date: Wednesday, March 11, 2026Time: 2:50 p.m. ETLocation: Miami, FL RBC Capital Markets Global Ophthalmology Conference Date: Wednesday, March 25, 2026Time: 11:45 a.m. ETLoc

    3/3/26 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gallagher Cam bought $323,693 worth of shares (164,000 units at $1.97) and was granted 33,000 shares, increasing direct ownership by 6% to 1,924,430 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/31/25 4:33:33 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Magrath George bought $97,600 worth of shares (100,000 units at $0.98), increasing direct ownership by 20% to 599,150 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/30/24 4:26:20 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Yerxa Benjamin R bought $9,834 worth of shares (10,000 units at $0.98), increasing direct ownership by 3% to 342,800 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    11/25/24 4:18:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    SEC Filings

    View All

    SEC Form DEF 14A filed by Opus Genetics Inc.

    DEF 14A - Opus Genetics, Inc. (0001228627) (Filer)

    3/23/26 4:06:05 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Opus Genetics Inc.

    S-3 - Opus Genetics, Inc. (0001228627) (Filer)

    3/13/26 4:56:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Opus Genetics Inc.

    PRE 14A - Opus Genetics, Inc. (0001228627) (Filer)

    3/12/26 4:58:34 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Opus Genetics with a new price target

    Cantor Fitzgerald initiated coverage of Opus Genetics with a rating of Overweight and set a new price target of $15.00

    3/30/26 8:19:42 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Opus Genetics with a new price target

    Oppenheimer initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00

    3/16/26 8:42:37 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Opus Genetics with a new price target

    BTIG Research initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $7.00

    1/20/26 9:23:30 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Leadership Updates

    Live Leadership Updates

    View All

    Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer. Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial

    9/2/25 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Opus Genetics Inc.

    SC 13D - Opus Genetics, Inc. (0001228627) (Subject)

    10/29/24 5:26:27 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Financials

    Live finance-specific insights

    View All

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

    Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive three-month data from the pediatric cohort

    9/30/25 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

    - Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, In

    8/13/25 4:30:00 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care